CA3113011C — Integrase inhibitors for the prevention of hiv
Assigned to Gilead Sciences Inc · Expires 2026-01-06 · 0y expired
What this patent protects
The present invention provides the use of a combination of bictegravir, or a pharmaceutically acceptable salt thereof, emtricitabine, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, for preventing an HIV inf…
USPTO Abstract
The present invention provides the use of a combination of bictegravir, or a pharmaceutically acceptable salt thereof, emtricitabine, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, for preventing an HIV infection in a subject, wherein said combination is for a first administration within or at about 24 hours after exposure of the subject to the HIV, and for a second administration of the combination within or at about 24 hours after the first administration.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.